Sbi Securities Co., Ltd. Inozyme Pharma, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.48 Trillion
- Q2 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 34 shares of INZY stock, worth $136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34
Previous 34
-0.0%
Holding current value
$136
Previous $31,000
338.71%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
81Shares Held
50MCall Options Held
13.8KPut Options Held
1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$20.6 Million0.01% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million5.72% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million0.29% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.87MShares$15.5 Million0.39% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.45MShares$13.8 Million0.19% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...